Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Financial Post - ATE in the canadian Biotech Boom
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Nov 25, 2020 10:30am
246 Views
Post# 31969164

RE:RE:Financial Post - ATE in the canadian Biotech Boom

RE:RE:Financial Post - ATE in the canadian Biotech BoomYes ... good article.

I like the following comment ...

Antibe and Fusion share an approach to drug development in that they’re backing a platform for delivery, not one specific drug, which gives them more chances for success, says Richard Bozzato, a senior advisor at MaRs Discovery District, an entrepreneurial incubator in Toronto.

What makes sense to me (as Dan alluded to in BioPUB) is the value of the academic work they are doing (likely related to new IP).  If they are on the heels of a more efficient delivery mechanism then it affects everything from ATB-340 (initially) to very accurate tunig and specific purposes (like the central sleep apnea example on ATE's facebook page).  It then translates to the future of 346 and 352 and the financial modeling of the value of this company.

Strap on that belt my little minions ... we are in for the ride of our lives.

Hoping the coming update gives us more details ... where we only have our imagination playing with us right now.

This company has the brain-power and I'm thinking they've been putting the strategy together perfectly timed to negotiations with Big Pharma.  I sure hope this is correct.

Good Luck My Longs !!!!!!  The time is upon us.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities